Serum ADAM17 Levels Pre-antiviral Therapy Correlate with HIV Patient Immune Reconstitution

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Dec 24

PMID 39717606

Authors

Ying Lin

Ming Chen

Xuelian Zhu

Xiaoya Cui

Suyu Sun

Xingzhong Hu

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between tumour necrosis factor (TNF) levels and disease progression is well-established. However, the impact of changes in the level of TNF hydrolase (A-disintegrin and metalloenzyme 17; ADAM17) in HIV patients remains to be fully elucidated.

Methods: Between March 1 and December 31, 2017, data were collected from 64 HIV-positive individuals in Wenzhou. Based on their history of antiviral treatment at the time of enrollment, these patients were categorized into two cohorts: an antiviral-treated group and an untreated HIV group. Then, the serum ADAM17 levels of each group were measured and analysed.

Results: In comparison to the antiviral-treated group and the control group, the untreated HIV group exhibited a significantly elevated serum ADAM17 level (p < 0.001). A significant negative correlation was observed between serum ADAM17 levels and CD4 T cell counts in the untreated HIV group (r = -0.486, p = 0.001). ROC curve analysis revealed that the pre-treatment serum ADAM17 level in the untreated HIV group had moderate diagnostic accuracy for the AIDS stage (area under the curve: 0.703, p = 0.028). Additionally, serum ADAM17 levels were positively correlated with ADAM17 expression on the surface of leukocytes (r = 0.367, p = 0.018).

Conclusion: Serum ADAM17 levels are significantly elevated in HIV patients and are correlated with disease progression and immune reconstitution.

References

Black R, Rauch C, Kozlosky C, Peschon J, Slack J, Wolfson M . A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385(6618):729-33. DOI: 10.1038/385729a0. View

Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y . HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic. 2009; 11(1):110-22. PMC: 2796297. DOI: 10.1111/j.1600-0854.2009.01006.x. View

Lisi S, DAmore M, Sisto M . ADAM17 at the interface between inflammation and autoimmunity. Immunol Lett. 2014; 162(1 Pt A):159-69. DOI: 10.1016/j.imlet.2014.08.008. View

Lee J, Wittki S, Brau T, Dreyer F, Kratzel K, Dindorf J . HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell. 2013; 49(4):668-79. DOI: 10.1016/j.molcel.2012.12.004. View

Gallitano S, McDermott L, Brar K, Lowenstein E . Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016; 74(5):974-80. DOI: 10.1016/j.jaad.2015.11.043. View

Fauci A . Host factors and the pathogenesis of HIV-induced disease. Nature. 1996; 384(6609):529-34. DOI: 10.1038/384529a0. View

Lee J, Schierer S, Blume K, Dindorf J, Wittki S, Xiang W . HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune Pathogenesis in Chronic HIV Infection. EBioMedicine. 2016; 6:103-113. PMC: 4856776. DOI: 10.1016/j.ebiom.2016.03.004. View

Arenaccio C, Chiozzini C, Columba-Cabezas S, Manfredi F, Affabris E, Baur A . Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol. 2014; 88(19):11529-39. PMC: 4178784. DOI: 10.1128/JVI.01712-14. View

Kononchik J, Ireland J, Zou Z, Segura J, Holzapfel G, Chastain A . HIV-1 targets L-selectin for adhesion and induces its shedding for viral release. Nat Commun. 2018; 9(1):2825. PMC: 6053365. DOI: 10.1038/s41467-018-05197-2. View

10.

Quaranta M, Mattioli B, Giordani L, Viora M . The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS. FASEB J. 2006; 20(13):2198-208. DOI: 10.1096/fj.06-6260rev. View

11.

Lee J, Ostalecki C, Zhao Z, Kesti T, Bruns H, Simon B . HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles. EBioMedicine. 2018; 28:151-161. PMC: 5836510. DOI: 10.1016/j.ebiom.2018.01.004. View

12.

Trible R, Emert-Sedlak L, Smithgall T . HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem. 2006; 281(37):27029-38. PMC: 2892265. DOI: 10.1074/jbc.M601128200. View

13.

Ramon-Luing L, Ocana-Guzman R, Tellez-Navarrete N, Preciado-Garcia M, Romero-Rodriguez D, Espinosa E . High Levels of TNF-α and TIM-3 as a Biomarker of Immune Reconstitution Inflammatory Syndrome in People with HIV Infection. Life (Basel). 2021; 11(6). PMC: 8227006. DOI: 10.3390/life11060527. View

14.

Gunda D, Kidenya B, Mshana S, Kilonzo S, Mpondo B . Accuracy of WHO immunological criteria in identifying virological failure among HIV-infected adults on First line antiretroviral therapy in Mwanza, North-western Tanzania. BMC Res Notes. 2017; 10(1):45. PMC: 5240422. DOI: 10.1186/s13104-016-2334-6. View

15.

Anglemyer A, Rutherford G, Easterbrook P, Horvath T, Vitoria M, Jan M . Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review. AIDS. 2014; 28 Suppl 2:S105-18. DOI: 10.1097/QAD.0000000000000232. View